Litcius/Paper detail

OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

C.M. Rudin, H.R. Kim, A. Navarro, M. Gottfried, S. Peters, T. Csőszi, P.K. Cheema, Delvis Rodríguez-Abreu, M. Wollner, G. Czyżewicz, J.C.-H. Yang, J. Mazieres, F.J. Orlandi, A. Luft, M. Gümüş, T. Kato, G.P. Kalemkerian, W. Fu, B. Zhao, H. El-Osta, M.M. Awad

2022Journal of Thoracic Oncology17 citationsDOI

Topics & Concepts

PembrolizumabMedicinePlaceboEtoposideInternal medicineOncologyChemotherapyImmunotherapyPathologyCancerAlternative medicineLung Cancer Research StudiesPancreatic and Hepatic Oncology ResearchNanoparticle-Based Drug Delivery